CA3079011A1 - Detection of symmetrical dimethylarginine - Google Patents
Detection of symmetrical dimethylarginine Download PDFInfo
- Publication number
- CA3079011A1 CA3079011A1 CA3079011A CA3079011A CA3079011A1 CA 3079011 A1 CA3079011 A1 CA 3079011A1 CA 3079011 A CA3079011 A CA 3079011A CA 3079011 A CA3079011 A CA 3079011A CA 3079011 A1 CA3079011 A1 CA 3079011A1
- Authority
- CA
- Canada
- Prior art keywords
- sdma
- antibody
- affinity
- protein
- analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 title claims abstract description 50
- NWGZOALPWZDXNG-LURJTMIESA-N (2s)-5-(diaminomethylideneamino)-2-(dimethylamino)pentanoic acid Chemical compound CN(C)[C@H](C(O)=O)CCCNC(N)=N NWGZOALPWZDXNG-LURJTMIESA-N 0.000 title claims abstract description 16
- 238000001514 detection method Methods 0.000 title abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 101
- 239000007790 solid phase Substances 0.000 claims abstract description 87
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 83
- 150000001483 arginine derivatives Chemical class 0.000 claims abstract description 59
- 238000003018 immunoassay Methods 0.000 claims abstract description 25
- 239000002245 particle Substances 0.000 claims description 222
- 235000018102 proteins Nutrition 0.000 claims description 129
- 102000004169 proteins and genes Human genes 0.000 claims description 129
- 108090000623 proteins and genes Proteins 0.000 claims description 129
- 239000000203 mixture Substances 0.000 claims description 85
- 239000007787 solid Substances 0.000 claims description 85
- 239000012491 analyte Substances 0.000 claims description 80
- 239000011159 matrix material Substances 0.000 claims description 71
- 210000002966 serum Anatomy 0.000 claims description 58
- 102100031126 6-phosphogluconolactonase Human genes 0.000 claims description 54
- 108010029731 6-phosphogluconolactonase Proteins 0.000 claims description 54
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims description 54
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 54
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 50
- 229940098773 bovine serum albumin Drugs 0.000 claims description 50
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 claims description 44
- NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 claims description 20
- 108010058846 Ovalbumin Proteins 0.000 claims description 17
- 229940092253 ovalbumin Drugs 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 10
- 229930064664 L-arginine Natural products 0.000 claims description 10
- 235000014852 L-arginine Nutrition 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 8
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 108090001008 Avidin Proteins 0.000 claims description 5
- 108010090804 Streptavidin Proteins 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000206602 Eukaryota Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 11
- 238000003556 assay Methods 0.000 abstract description 84
- 239000000523 sample Substances 0.000 abstract description 65
- 241001465754 Metazoa Species 0.000 abstract description 18
- 239000012472 biological sample Substances 0.000 abstract description 8
- 238000002967 competitive immunoassay Methods 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 69
- 210000002381 plasma Anatomy 0.000 description 42
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- 239000000427 antigen Substances 0.000 description 32
- 239000003054 catalyst Substances 0.000 description 32
- 102000036639 antigens Human genes 0.000 description 31
- 108091007433 antigens Proteins 0.000 description 31
- 238000009739 binding Methods 0.000 description 30
- 230000027455 binding Effects 0.000 description 29
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 25
- 229920000126 latex Polymers 0.000 description 25
- 239000004816 latex Substances 0.000 description 25
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 23
- 239000000872 buffer Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 20
- 239000007788 liquid Substances 0.000 description 20
- 229920005989 resin Polymers 0.000 description 20
- 239000011347 resin Substances 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 18
- -1 glucaronate Chemical compound 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 239000003085 diluting agent Substances 0.000 description 16
- 241000282465 Canis Species 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 239000011248 coating agent Substances 0.000 description 15
- 238000000576 coating method Methods 0.000 description 15
- 239000007987 MES buffer Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 150000003573 thiols Chemical class 0.000 description 14
- 238000011088 calibration curve Methods 0.000 description 12
- 230000009870 specific binding Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- VRDGQQTWSGDXCU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-iodoacetate Chemical compound ICC(=O)ON1C(=O)CCC1=O VRDGQQTWSGDXCU-UHFFFAOYSA-N 0.000 description 11
- 150000007942 carboxylates Chemical class 0.000 description 11
- 125000005647 linker group Chemical group 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000001994 activation Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 229920001213 Polysorbate 20 Polymers 0.000 description 9
- 230000021615 conjugation Effects 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 208000017169 kidney disease Diseases 0.000 description 9
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 9
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 9
- 239000011550 stock solution Substances 0.000 description 9
- 241000282324 Felis Species 0.000 description 8
- 206010020850 Hyperthyroidism Diseases 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 7
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 7
- 102100031013 Transgelin Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 125000003396 thiol group Chemical group [H]S* 0.000 description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 239000004793 Polystyrene Substances 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 229920002223 polystyrene Polymers 0.000 description 6
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 6
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- ANSCABGFLRQFHU-UHFFFAOYSA-N 3-(methylamino)-3-oxopropanoic acid Chemical compound CNC(=O)CC(O)=O ANSCABGFLRQFHU-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 208000020446 Cardiac disease Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 150000004679 hydroxides Chemical class 0.000 description 3
- 229960003151 mercaptamine Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000036963 noncompetitive effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- 239000006226 wash reagent Substances 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- WDCYWAQPCXBPJA-UHFFFAOYSA-N 1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1 WDCYWAQPCXBPJA-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000237988 Patellidae Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- WFLQAMUOBIONDG-UHFFFAOYSA-N phenoxyarsonic acid Chemical compound O[As](O)(=O)OC1=CC=CC=C1 WFLQAMUOBIONDG-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012536 storage buffer Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100034368 Potassium voltage-gated channel subfamily A member 1 Human genes 0.000 description 1
- 101710154114 Potassium voltage-gated channel subfamily A member 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004699 Ultra-high molecular weight polyethylene Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical class [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574592P | 2017-10-19 | 2017-10-19 | |
| US62/574,592 | 2017-10-19 | ||
| US201762599117P | 2017-12-15 | 2017-12-15 | |
| US62/599,117 | 2017-12-15 | ||
| PCT/US2018/056687 WO2019079707A1 (en) | 2017-10-19 | 2018-10-19 | SYMMETRIC DIMETHYLARGININE DETECTION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3079011A1 true CA3079011A1 (en) | 2019-04-25 |
Family
ID=66170983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3079011A Pending CA3079011A1 (en) | 2017-10-19 | 2018-10-19 | Detection of symmetrical dimethylarginine |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11422136B2 (enExample) |
| EP (1) | EP3697499A4 (enExample) |
| JP (1) | JP7398366B2 (enExample) |
| KR (1) | KR20250034534A (enExample) |
| CN (1) | CN111246918B (enExample) |
| AU (1) | AU2018351349B2 (enExample) |
| CA (1) | CA3079011A1 (enExample) |
| MX (1) | MX2020003523A (enExample) |
| TW (1) | TWI831753B (enExample) |
| WO (1) | WO2019079707A1 (enExample) |
| ZA (1) | ZA202002415B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20201734T1 (hr) * | 2008-08-07 | 2021-03-19 | Idexx Laboratories, Inc. | Postupci za detektiranje simetričnog dimetilarginina |
| CA3255043A1 (en) * | 2015-02-20 | 2025-04-02 | Idexx Laboratories, Inc. | Homogenous immunoassay with compensation for background signal |
| MX2020003523A (es) | 2017-10-19 | 2020-07-22 | Idexx Lab Inc | Deteccion de dimetilarginina simetrica. |
| US10745492B1 (en) * | 2019-04-03 | 2020-08-18 | Ark Diagnostics, Inc. | Antibodies to symmetrically dimethylated arginine analytes and use thereof |
| CA3152793A1 (en) | 2019-09-05 | 2021-03-11 | The Regents Of The University Of California | Noninvasive method to quantify kidney function and functional decline |
| CN113125697B (zh) * | 2019-12-31 | 2024-03-26 | 科美博阳诊断技术(上海)有限公司 | 一种睾酮均相化学发光检测试剂盒及其应用 |
| EP4136141A4 (en) * | 2020-04-17 | 2024-09-11 | IDEXX Laboratories, Inc. | Fluorescence quenching immunossay |
| WO2022133159A1 (en) | 2020-12-17 | 2022-06-23 | Nephrosant, Inc. | Kits for stabilization of urine samples |
| WO2025070448A1 (ja) * | 2023-09-26 | 2025-04-03 | 富士フイルム株式会社 | 対称性ジメチルアルギニンを測定するためのキットおよび対称性ジメチルアルギニンの測定方法 |
| WO2025205769A1 (ja) * | 2024-03-26 | 2025-10-02 | 富士フイルム株式会社 | α－アミラーゼと対称性ジメチルアルギニンとのコンジュゲート、およびその応用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3875011A (en) | 1972-11-06 | 1975-04-01 | Syva Co | Enzyme immunoassays with glucose-6-phosphate dehydrogenase |
| DE3134787A1 (de) | 1981-09-02 | 1983-03-10 | Boehringer Mannheim Gmbh, 6800 Mannheim | Creatinin-antikoerper |
| IT1199088B (it) * | 1984-03-09 | 1988-12-30 | Miles Italiana | Saggio di legame specifico mediante impiego di anti-g6pdh come marcante |
| US4818703A (en) | 1985-10-23 | 1989-04-04 | Pizzolante John M | Stabilized alkaline picrate reagent for jaffe creatinine determination |
| EP0356160A3 (en) | 1988-08-24 | 1991-09-11 | The Board Of Trustees Of The Leland Stanford Junior University | Capillary device |
| US5238652A (en) * | 1990-06-20 | 1993-08-24 | Drug Screening Systems, Inc. | Analytical test devices for competition assay for drugs of non-protein antigens using immunochromatographic techniques |
| US5726010A (en) | 1991-07-31 | 1998-03-10 | Idexx Laboratories, Inc. | Reversible flow chromatographic binding assay |
| US6455288B1 (en) | 1993-04-08 | 2002-09-24 | Dade Behring Marburg Gmbh | Homogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases |
| US5710009A (en) * | 1994-02-17 | 1998-01-20 | Serex, Inc. | Receptor:release ligand (reland) complexes and release assays using said reland and methods and kits based thereon |
| US5804452A (en) | 1995-04-27 | 1998-09-08 | Quidel Corporation | One step urine creatinine assays |
| WO1998049199A1 (en) | 1997-05-01 | 1998-11-05 | Panorama Research, Inc. | Cardiovascular disease risk assessment |
| US6736957B1 (en) | 1997-10-16 | 2004-05-18 | Abbott Laboratories | Biosensor electrode mediators for regeneration of cofactors and process for using |
| US6358699B1 (en) | 1999-02-05 | 2002-03-19 | Cooke Pharma | Assay for asymmetrical NG, NG dimethyl-l-arginine |
| AU2452301A (en) | 1999-12-22 | 2001-07-03 | Research Foundation Of The State University Of New York, The | Protein methylarginine-specific antibodies |
| AU2001275870A1 (en) * | 2000-07-06 | 2002-01-21 | Fal Diagnostics | Methods and kits for the detection of arginine compounds |
| ATE391912T1 (de) | 2000-07-12 | 2008-04-15 | Naser Werner Dr | Direkte bestimmung des quotients von analyt- zu referenzmolekülen |
| DE10040904A1 (de) | 2000-08-18 | 2002-02-28 | Boeger Rainer H | Verfahren und Mittel zum Nachweis einer Wahrscheinlichkeit zukünftigen Fortschreitens von Gefässerkrankungen |
| US7241856B2 (en) | 2003-06-02 | 2007-07-10 | Pentron Clinical Technologies Llc | Dental resins, dental composite materials, and method of manufacture thereof |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP4214271B2 (ja) | 2002-10-15 | 2009-01-28 | アークレイ株式会社 | クレアチニン測定用試験片 |
| US7501053B2 (en) | 2002-10-23 | 2009-03-10 | Abbott Laboratories | Biosensor having improved hematocrit and oxygen biases |
| WO2004046314A2 (en) * | 2002-11-15 | 2004-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for detecting asymmetric dimethylarginine in a biological sample |
| JP2004279412A (ja) * | 2003-02-24 | 2004-10-07 | Sanwa Kagaku Kenkyusho Co Ltd | 低分子化合物の免疫学的測定・検出方法 |
| US20050148029A1 (en) | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
| US7867780B2 (en) * | 2004-03-30 | 2011-01-11 | Whatman, Inc. | Lateral flow format, materials and methods |
| ES2332218T3 (es) | 2004-11-04 | 2010-01-29 | Germediq Forschungs- Und Entwicklungsgesellschaft Mbh | Metodo para la determinacion de arginina, argininas metiladas y sus derivados. |
| CN1786713A (zh) * | 2004-12-09 | 2006-06-14 | 陈金华 | 酶标仪在胶乳增强免疫透射比浊法中的应用 |
| US7879979B2 (en) * | 2005-01-21 | 2011-02-01 | Alere International | Arginine analogs, and methods for their synthesis and use |
| EP3144675A1 (en) * | 2005-04-28 | 2017-03-22 | Ventana Medical Systems, Inc. | Enzymes conjugated to antibodies via a peg heterobifuctional linker |
| DE102005060057A1 (de) | 2005-12-15 | 2007-06-28 | Kellner, Karl-Heinz, Dr. | Sandwich-Immunoassay für kleine Haptenmoleküle |
| JP2007176872A (ja) | 2005-12-28 | 2007-07-12 | Sentan Seimei Kagaku Kenkyusho:Kk | アシンメトリックジメチルアルギニンを認識する抗体及びその製造方法並びに翻訳後修飾アミノ酸含有タンパク質の検出方法 |
| FR2919063B1 (fr) | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal. |
| JP5385914B2 (ja) | 2007-12-05 | 2014-01-08 | キングス カレッジ ロンドン | 方法及び組成物 |
| HRP20201734T1 (hr) * | 2008-08-07 | 2021-03-19 | Idexx Laboratories, Inc. | Postupci za detektiranje simetričnog dimetilarginina |
| WO2010139341A1 (en) | 2009-06-02 | 2010-12-09 | Biocrates Life Sciences Ag | New biomarkers for assessing kidney diseases |
| CN101587118B (zh) | 2009-07-03 | 2012-09-12 | 长春迪瑞医疗科技股份有限公司 | 肌酐尿液分析试纸及制备方法 |
| CN101598727B (zh) | 2009-07-09 | 2012-10-10 | 上海科华生物工程股份有限公司 | 定量测定人体血液尿素含量的干化学试纸 |
| CN101865911A (zh) | 2010-03-16 | 2010-10-20 | 苏州市玮琪生物科技有限公司 | 一种尿肌酐定量检测卡 |
| US9976959B2 (en) * | 2010-08-31 | 2018-05-22 | Konica Minolta Medical & Graphic, Inc. | Biological substance detection method using florescent dye-containing particle |
| DE102011055265A1 (de) | 2010-11-17 | 2012-05-24 | Karl-Heinz Kellner | Automatenfähiger Immunoassay für biogene Amine |
| JP2012112785A (ja) | 2010-11-24 | 2012-06-14 | Tohoku Univ | 透析膜の評価方法 |
| US8394647B2 (en) * | 2011-02-17 | 2013-03-12 | Siemens Healthcare Diagnostics Inc. | Reducing non-covalently bound polysaccharide on supports |
| CN102628868B (zh) * | 2011-12-30 | 2014-09-17 | 北京九强生物技术股份有限公司 | 检测非对称二甲基精氨酸含量的胶乳增强免疫比浊法试剂盒 |
| JP6373191B2 (ja) | 2012-01-10 | 2018-08-15 | アイデックス ラボラトリーズ インコーポレイテッドＩＤＥＸＸ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． | 免疫学的検定用試験スライド |
| US20140038203A1 (en) | 2012-07-09 | 2014-02-06 | Musc Foundation For Research Development | Methods for detecting or predicting kidney disease |
| PT3305784T (pt) | 2012-08-21 | 2020-10-23 | Janssen Pharmaceutica Nv | Haptenos de quetiapina para utilização em ensaios imunológicos |
| EP3041576B1 (en) * | 2013-09-05 | 2019-06-19 | IDEXX Laboratories, Inc. | Methods for detecting renal disease |
| CA3255043A1 (en) | 2015-02-20 | 2025-04-02 | Idexx Laboratories, Inc. | Homogenous immunoassay with compensation for background signal |
| MX2020003523A (es) | 2017-10-19 | 2020-07-22 | Idexx Lab Inc | Deteccion de dimetilarginina simetrica. |
| CN108469419A (zh) * | 2018-03-09 | 2018-08-31 | 山东泰邦生物制品有限公司 | 采用酶标仪免疫透射比浊法高通量检测IgG含量的方法 |
-
2018
- 2018-10-19 MX MX2020003523A patent/MX2020003523A/es unknown
- 2018-10-19 JP JP2020521964A patent/JP7398366B2/ja active Active
- 2018-10-19 TW TW107136895A patent/TWI831753B/zh active
- 2018-10-19 US US16/165,337 patent/US11422136B2/en active Active
- 2018-10-19 EP EP18868800.6A patent/EP3697499A4/en active Pending
- 2018-10-19 KR KR1020257007101A patent/KR20250034534A/ko active Pending
- 2018-10-19 AU AU2018351349A patent/AU2018351349B2/en active Active
- 2018-10-19 WO PCT/US2018/056687 patent/WO2019079707A1/en not_active Ceased
- 2018-10-19 CN CN201880068370.5A patent/CN111246918B/zh active Active
- 2018-10-19 CA CA3079011A patent/CA3079011A1/en active Pending
-
2020
- 2020-05-04 ZA ZA2020/02415A patent/ZA202002415B/en unknown
-
2022
- 2022-07-29 US US17/877,410 patent/US20230102277A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202002415B (en) | 2023-09-27 |
| US20190120856A1 (en) | 2019-04-25 |
| CN111246918B (zh) | 2024-06-14 |
| TW201923349A (zh) | 2019-06-16 |
| WO2019079707A1 (en) | 2019-04-25 |
| US11422136B2 (en) | 2022-08-23 |
| CN111246918A (zh) | 2020-06-05 |
| KR20250034534A (ko) | 2025-03-11 |
| TWI831753B (zh) | 2024-02-11 |
| AU2018351349A1 (en) | 2020-04-23 |
| US20230102277A1 (en) | 2023-03-30 |
| EP3697499A4 (en) | 2021-07-21 |
| AU2018351349B2 (en) | 2025-08-14 |
| JP2021500551A (ja) | 2021-01-07 |
| MX2020003523A (es) | 2020-07-22 |
| EP3697499A1 (en) | 2020-08-26 |
| JP7398366B2 (ja) | 2023-12-14 |
| KR20200073259A (ko) | 2020-06-23 |
| BR112020007150A2 (pt) | 2020-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230102277A1 (en) | Detection of symmetrical dimethylarginine | |
| US20220221446A1 (en) | Methods for Detecting Symmetrical Dimethylarginine | |
| JPH0814579B2 (ja) | 特異的結合性物質の測定法及び試薬 | |
| US10458981B2 (en) | Three-step acid dissociation enzyme linked immunosorbent (TADELIS) assay | |
| JP2021181994A (ja) | 腎疾患の検出方法 | |
| JP7368867B2 (ja) | 対称性ジメチル化アルギニン分析物に対する抗体及びその用途 | |
| KR102902843B1 (ko) | 대칭 디메틸아르기닌의 검출 | |
| JP5817720B2 (ja) | 含硫黄アミノ酸誘導体 | |
| JPH03503566A (ja) | 天然結合タンパク質に対するモノクローナル抗体を用いたイムノアツセイ | |
| BR112020007150B1 (pt) | Métodos e kit para determinação de dimetilarginina simétrica (sdma) em uma amostra, dispositivo, reagente de captura, fase sólida e composição de um derivado de arginina | |
| US20240219379A1 (en) | Immunoassay device and method | |
| Cernoch et al. | Production and analytical characterization of neopterin immunoreagents for biosensor developments | |
| TW202204329A (zh) | 螢光淬滅免疫分析 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231018 |